Effects on mood of acute phenylalanine/tyrosine depletion in healthy women

Neuropsychopharmacology

Volumn 22, Issue 1, 2000, Pages 52-63

  Leyton, M ^a   Young, S N ^a   Pihl, R O ^a   Etezadi, S ^a   Lauze, C ^a   Blier, P ^a   Baker, G B ^b   Benkelfat, C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anxiety; Cardiovascular activity; Depression; Dopamine; Norepinephrine; Serotonin; Stress; Tryptophan

Indexed keywords

CATECHOLAMINE DERIVATIVE; DOPAMINE; NORADRENALIN; PHENYLALANINE; SEROTONIN; TRYPTOPHAN;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; ANXIETY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CATECHOLAMINE SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ENERGY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MOOD; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; AFFECT; AMINO ACIDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; NUTRITION PHYSIOLOGY; PHENYLALANINE; STRESS, PSYCHOLOGICAL; TRYPTOPHAN; TYROSINE;

EID: 0033990785     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00086-X     Document Type: Article

References (75)

1. Abercrombie E.D., Zigmond M.J. Modification of central catecholaminergic systems by stress and injury. Functional significance and clinical implications Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;355-361 Raven Press, New York.
2. Banderet L.E., Lieberman H.R. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull. 22:1989;759-762.
3. Beck A.T., Ward C.H., Mendelson M., Mock J.E., Erbaugh J.K. An inventory for measuring depression. Arch Gen Psychiat. 4:1961;561-571.
4. Bel N., Artigas F. Reduction of serotonergic function in rat brain by tryptophan depletion. Effects in control and fluvoxamine-treated rats J Neurochem. 67:1996;669-676.
5. Benkelfat C., Ellenbogen M.A., Dean P., Palmour R.M., Young S.N. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders Arch Gen Psychiat. 51:1994;687-697.
6. Biggio G., Porceddu M.L., Gessa G.L. Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3′,5′-monophosphate content in the rat caudate nucleus induced by the acute administration of an amino acid mixture lacking tyrosine and phenylalanine. J Neurochem. 26:1976;1253-1255.
7. Blackburn J.R., Pfaus J.G., Phillips A.G. Dopamine functions in appetitive and defensive behaviors. Prog Neurobiol. 39:1992;247-279.
8. Bond A., Lader M. The use of analog scales in rating subjective feelings. Br J Med Psychol. 47:1974;211-218.
9. Bremner J.D., Innis R.B., Salomon R.M., Staib L.H., Ng C.K., Miller H.L., Bronen R.A., Krystal J.H., Duncan J., Rich D., Price L.H., Malison R., Dey H., Soufer R., Charney D.S. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiat. 54:1997;364-374.
10. Broderick P.A. Alprazolam, diazepam, yohimbine, clonidine. In vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia Prog Neuropsychopharmacol Biol Psychiat. 21:1997;1117-1140.
11. Brogden R.N., Heel R.C., Speight T.M., Avery G.S. α-Methyl-p-tyrosine. A review of its pharmacology and clinical use Drugs. 21:1981;81-89.
12. Bunney W.E., Davis J.M. Norepinephrine in depressive reactions. Arch Gen Psychiat. 13:1965;483-494.
13. Carlsson A., Lindqvist M. Dependence of 5HT and catecholamine synthesis on concentrations of precursor amino acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 303:1978;157-164.
14. Carpenter L.L., Anderson G.M., Pelton G.H., Gudin J.A., Kirwin P.D.S., Price L.H., Heninger G.R., McDougle C.J. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology. 19:1998;26-35.
15. Charney D.S., Heninger G.R., Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder Arch Gen Psychiat. 41:1984;751-763.
16. Cleare A.J., Bond A.J. The effect of tryptophan depletion and enhancement on subjective and behavioral aggression in normal male subjects. Psychopharmacology. 118:1995;72-81.
17. Closse A., Frick W., Dravid A., Bolliger G., Hauser D., Sauter A., Tobler H.J. Classification of drugs according to receptor binding profiles. Naunyn Schmiedebergs Arch Pharmacol. 327:1984;95-101.
18. Cubeddu L.X., Hoffmann I.S., Talmaciu R.K. Is the release of dopamine from medial prefrontal cortex modulated by presynaptic receptors? Comparison with nigrostriatal and mesolimbic terminals. Ann NY Acad Sci. 604:1990;452-461.
19. Deijen J.B., Orlebeke J.F. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull. 33:1994;319-323.
20. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan Arch Gen Psychiat. 47:1990;411-418.
21. Depue R.A., Iocono W.G. Behavioral aspects of affective disorders. Ann Rev Psychol. 40:1989;457-492.
22. During M.J., Acworth I.N., Wurtman R.J. Effects of systemic L-tyrosine on dopamine release from rat corpus striatum and nucleus accumbens. Brain Res. 452:1988;378-380.
23. Ellenbogen M.A., Young S.N., Dean P., Palmour R.M., Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers. Sex differences and temporal stability Neuropsychopharmacology. 15:1996;465-474.
24. Engelman K., Horwitz D., Jéquier E., Sjoerdsma A. Biochemical and pharmacologic effects of α-methyltyrosine in man. J Clin Invest. 47:1968;577-591.
25. Fernstrom J.D., Wurtman R.J., Hammarstrom-Wiklund B., Rand W.M., Munro H.N., Davidson C.S. Diurnal variations in plasma concentrations of tryptophan, tyrosine, and other neutral amino acids. Effect of dietary protein intake Am J Clin Nutr. 32:1979;1912-1922.
26. Fernstrom M.H., Fernstrom J.D. Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. Life Sci. 57:1995;PL97-PL102.
27. Heslop K, Portas CM, Curzon G (1991): Effect of altered tryptophan availability on tissue and extracellular serotonin in the rat cortex. In Rollema H, Westerink BHC, Drijfhout WJ (eds), Monitoring Molecules in Neuroscience: Proceedings of the 5th International Conference of In Vivo Methods. pp 259-261.
28. Hjorth S., Carlsson A., Clark D., Svensson K., Wikstrom H., Sanchez D., Lindberg P., Hacksell U., Arvidsson L.E., Johansson A. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology. 81:1983;89-99.
29. Kendler K.S., Kessler R.C., Walters E.E., Maclean C., Neale M.C., Heath A.C., Eaves L.J. Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiat. 152:1995;833-842.
30. Kirschbaum C., Pirke K.M., Hellhammer D.H. The "Trier Social Stress Test" A tool for investigating psychobiological stress responses in a laboratory setting Neuropsychobiology. 28:1993;76-81.
31. Klaassen T., Riedel W.J., Deutz N.E.P., van Praag H.M. Specificity of the tryptophan depletion method. J Psychopharmacol. 11:1997;A33.
32. Koob G.F. Hedonic valence, dopamine and motivation. Mol Psychiat. 1:1996;186-189.
33. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiat. 12:1988;117-164.
34. Le Moal M. Mesocortical dopaminergic neurons. Functional and regulatory roles Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;283-294 Raven Press, New York.
35. Lemarquand D., Benkelfat C., Pihl R.O., Palmour R.M., Young S.N. Tryptophan depletion-induced behavioral disinhibition in nonalcoholic young men with multigenerational family histories of paternal alcoholism. Am J Psychiat. in press:1999.
36. Lorr M., McNair D.M., Fisher S. Evidence for bipolar mood states. J Pers Assess. 46:1982;432-436.
37. McCann U.D., Penetar D.M., Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol. 13:1990;565-568.
38. McCann U.D., Penetar D.M., Shaham Y., Thorne D.R., Sing H.C., Thomas M.L., Gillin J.C., Belenky G. Effects of catecholamine depletion on alertness and mood in rested and sleep-deprived normal volunteers. Neuropsychopharmacology. 8:1993;345-356.
39. McCann U.D., Thorne D., Hall M., Popp K., Avery W., Sing H., Thomas M., Belenky G. The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety Neuropsychopharmacology. 13:1995;41-52.
40. McNair D.M., Lorr M., Droppleman L.F. Manual for the Profile of Mood States. 1988;Educational and Industrial Testing Service, San Diego.
41. Milner J.D., Wurtman R.J. Catecholamine synthesis. Physiological coupling to precursor supply Biochem Pharmacol. 35:1986;875-881.
42. Moja E.A., Antinoro E., Cesa-Bianchi M., Gessa G.L. Increases in stage 4 sleep after ingestion of a tryptophan-free diet in humans. Pharmacol Res Commun. 16:1984;909-914.
43. Moja E.A., Restani P., Corsini E., Stacchezzini M.C., Assereto R., Galli C.L. Cycloheximide blocks the fall of plasma and tissue tryptophan levels after tryptophan-free amino acid mixtures. Life Sci. 49:1991;1121-1128.
44. Moja E.A., Lucini V., Benedetti F., Lucca A. Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man. Life Sci. 58:1996;2389-2395.
45. Moroni F., Tanganelli S., Antonelli T., Carla V., Bianchi C., Beani L. Modulation of cortical acetylcholine and gamma-aminobutyric acid release in freely moving guinea pigs. Effects of clonidine and other adrenergic drugs J Pharmacol Exp Ther. 227:1983;435-440.
46. Neri D.F., Wiegmann D., Stanny R.R., Shappell S.A., McCardie A., McKay D.L. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med. 66:1995;313-319.
47. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., Blier P., Diksic M. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA. 94:1997;5308-5313.
48. Oldendorf W.H., Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol. 230:1976;94-98.
49. Palmour R.M., Ervin F.R., Baker G.B., Young S.N. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology. 136:1998;1-7.
50. Pihl R.O., Young S.N., Harden P., Plotnick S., Chamberlain B., Ervin F.R. Acute effect of altered tryptophan levels and alcohol on aggression in normal human males. Psychopharmacology. 119:1995;353-360.
51. Pitchot W., Ansseau M., Gonzalez Moreno A., Hansenne M., von Frenckell R. Dopaminergic function in panic disorder. Comparison with a major and minor depression Biol Psychiat. 32:1992;1004-1011.
52. Przedborski S., Levivier M., Raftopoulos C., Naini A.B., Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Movement Disord. 10:1995;28-36.
53. Redmond D.E., Katz M.M., Maas J.W., Swann A., Casper R., Davis J.M. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects Arch Gen Psychiat. 43:1986;938-947.
54. Redmond D.E. Studies of the nucleus locus coeruleus in monkeys and hypotheses for neuropsychopharmacology. Meltzer H.Y. Psychopharmacology. The Third Generation of Progress:1987;967-975 Raven Press, New York.
55. Schatzberg A.F., Schildkraut J.J. Recent studies on norepinephrine systems in mood disorders. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;911-920 Raven Press, New York.
56. Schildkraut J.J. The catecholamine hypothesis of affective disorders. A review of supporting evidence Am J Psychiat. 122:1965;509-522.
57. Schildkraut J.J. Current status of the catecholamine hypothesis of affective disorders. Lipton M.A., DiMascio A., Killam K.F. Psychopharmacology. A Generation of Progress:1978;1223-1234 Raven Press, New York.
58. Sheehan B.D., Tharyan P., McTavish S.F.B., Campling G.M., Cowen P.J. The use of dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. J Psychopharmacol. 10:1996;231-234.
59. Siever L.J. Role of noradrenergic mechanisms in the etiology of the affective disorders. Meltzer H.Y. Psychopharmacology. The Third Generation of Progress:1987;493-504 Raven Press, New York.
60. Sjoerdsma A., Engelman K., Spector S., Udenfriend S. Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet. ii:1965;1092-1094.
61. Sloley B.D., Kah O., Trudeau V.L., Dulka J.G., Peter R.E. Amino acid neurotransmitters and dopamine in brain and pituitary of the goldfish. Involvement in the regulation of gonadotrophin secretion J Neurochem. 58:1992;2245-2262.
62. Smith S.E., Pihl R.O., Young S.N., Ervin F.R. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males. Psychopharmacology. 91:1987;451-457.
63. Spitzer R.L. Structured Clinical Interview for DSM-IIIR. 1987;Biometrics Research Department, New York State Psychiatric Institute, New York.
64. Stancampiano R., Melis F., Sarais L., Cocco S., Cugusi C., Fadda F. Acute administration of a tryptophan-free amino acid mixture decreases 5-HT release in rat hippocampus in vivo. Am J Physiol. 272:1997;R991-R994.
65. Stewart J. How does incentive motivational theory apply to sexual behavior? Bancroft J. The Pharmacology of Sexual Function. 1995;3-11 Elsevier Science, Amsterdam.
66. Tam S.Y., Elsworth J.D., Bradberry C.W., Roth R.H. Mesocortical dopamine neurons. High basal firing frequency predicts tyrosine dependence of dopamine synthesis J Neural Transm. 81:1990;97-110.
67. Tam S.Y., Roth R.H. Mesoprefrontal dopaminergic neurons. Can tyrosine availability influence their functions? Biochem Pharmacol. 53:1997;441-453.
68. Trestman R.L., Coccaro E.F., Bernstein D., Lawrence T., Gabriel S.M., Horvath T.B., Siever L.J. Cortisol responses to mental arithmetic in acute and remitted depression. Biol Psychiat. 29:1991;1051-1054.
69. Wilkins K. Eosinophilia-myalgia syndrome. Can Med Assoc J. 142:1990;1265-1266.
70. Willner P. Dopaminergic mechanisms in depression and mania. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;921-931 Raven Press, New York.
71. Wise R.A. Addictive drugs and brain stimulation reward. Ann Rev Neurosci. 19:1996;319-340.
72. Wolf M.E., Galloway M.P., Roth R.H. Regulation of dopamine synthesis in the medial prefrontal cortex. Studies in brain slices J Pharmacol Exp Ther. 236:1986;699-707.
73. Wong J.T., Baker G.B., Coutts R.T. A rapid, sensitive assay for gamma-aminobutyric acid in brain using electron-capture gas chromatography. Res Commun Chem Pathol Pharmacol. 70:1990;115-124.
74. Yocca F.D. Neurochemistry and neurophysiology of buspirone and gepirone. Interactions at presynaptic and postsynaptic 5-HT1A receptors J Clin Psychopharmacol. 10:1990;6S-12S.
75. Young S.N., Smith S.E., Pihl R.O., Ervin F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 87:1985;173-177.